<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01714414</url>
  </required_header>
  <id_info>
    <org_study_id>LMU-IMPH-FATI-01</org_study_id>
    <nct_id>NCT01714414</nct_id>
  </id_info>
  <brief_title>A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA &lt;50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen</brief_title>
  <acronym>FATI-01</acronym>
  <official_title>A Prospective, Multicenter, Open, Randomized Phase 2a Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA &lt;50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen After 24 Weeks of Treatment in ART naïve, Non Subtype B HIV-1 Infected Individuals From Tanzania and Ivory Coast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Hoelscher</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Medical Research, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Treichville Academic hospital center, Division of infectious and tropical diseases (SMIT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kumasi Centre for Collaborative Research (KCCR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bernhard Nocht Institute for Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmaceutical Company (Chiracon GmbH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmaceutical Company (STADA Vietnam Joint Venture Co. Ltd.)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, open, randomized Phase 2a trial to confirm a sustained&#xD;
      virological suppression defined as HIV-RNA &lt;50 copies/ml of 3 different doses of Fozivudine&#xD;
      in context to a standard Zidovudine based antiretroviral therapy regimen after 24 weeks of&#xD;
      treatment in ART naïve, non subtype B HIV-1 infected individuals from Tanzania and Ivory&#xD;
      Coast.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate four different oral 1st line antiretroviral regimens: three study&#xD;
      arms will contain different doses of Fozivudine (FZD) plus Lamivudine (3TC) in a twice daily&#xD;
      or once daily application plus once daily Efavirenz. The 4th study arm will contain standard&#xD;
      Zidovudine (AZT)/Lamivudine (3TC) twice daily in a fixed dose combination plus once daily&#xD;
      Efavirenz. The treatment duration will be 24 weeks.&#xD;
&#xD;
      In a pharmacokinetic Sub-Study Pharmacokinetic (PK) characteristics will be determined under&#xD;
      controlled conditions in a sub population to evaluate PK values of the study drugs.&#xD;
&#xD;
      Primary Objective&#xD;
&#xD;
      The primary objective is to confirm a sustained virological suppression (HIV RNA &lt;50&#xD;
      copies/ml) after 24 weeks of treatment between three different doses of Fozivudine (FZD)&#xD;
      based antiretroviral 1st line treatment regimen in context to a standard Zidovudine (ZDV)&#xD;
      based treatment regimen in non subtype B HIV-1 infected individuals from Africa.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        1. HIV-RNA log10 reduction of HIV-RNA at 2, 4 and 8 weeks of treatment between different&#xD;
           arms&#xD;
&#xD;
        2. Virological response (HIV RNA &lt;50 copies/ml) at 8 and 12 weeks of treatment between&#xD;
           different arms&#xD;
&#xD;
        3. Virological response (HIV RNA &lt;400 copies/ml) at 8, 12 and 24 weeks of treatment between&#xD;
           different arms&#xD;
&#xD;
        4. Immunologic response: variation in CD4 lymphocytes between different arms&#xD;
&#xD;
        5. Drug toxicity, particularly anaemia, neutropenia and gastrointestinal adverse events&#xD;
&#xD;
        6. Resistance pattern for in patients with virological failure&#xD;
&#xD;
        7. Clinical trial capacity building of African study sites within the FATI network&#xD;
&#xD;
        8. Establishment of a Fozivudine Drug developing consortium (NET) including members of&#xD;
           pharmaceutical manufacturers in Asia, Africa and Europe.&#xD;
&#xD;
        9. Development and piloting of a capacity development monitoring and evaluation framework&#xD;
&#xD;
      Pharmacological Objectives&#xD;
&#xD;
        1. Pharmacokinetic assessments after the first intake of study drugs in a subset of study&#xD;
           participants (Pharmacokinetic sub study)&#xD;
&#xD;
        2. Pharmacokinetic assessments at steady state after four weeks of study drugs in a subset&#xD;
           of study participants (Pharmacokinetic sub study)&#xD;
&#xD;
      Study Population and Study Duration&#xD;
&#xD;
      A total of 120 ART naive HIV-1 infected individuals with the indication to start&#xD;
      antiretroviral treatment according to WHO and country guidelines will be enrolled at two&#xD;
      study sites in Côte d'Ivoire and Tanzania. Each of the two sites will enroll 60 participants&#xD;
      (15 participants per arm). For the PK Sub-Study 6 participants per study arm (total 24&#xD;
      participants will be included.&#xD;
&#xD;
      A minimum of 30% gender representation (female or male) participants will be requested per&#xD;
      site. Recruitment, screening and enrollment of study participants are expected to be&#xD;
      completed after 9 months. Patient treatment is 24 weeks. So patient related study procedures&#xD;
      will take 15 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with plasma HIV RNA &lt; 50 copies/ml</measure>
    <time_frame>at week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with plasma HIV RNA &lt;50 copies/ml</measure>
    <time_frame>at week 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with plasma HIV RNA &lt; 400 copies/ml</measure>
    <time_frame>at week 8, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean HIV log10 reduction compared to baseline</measure>
    <time_frame>at week 2, 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of circulating total lymphocyte count</measure>
    <time_frame>up to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of circulating CD4+ lymphocyte count</measure>
    <time_frame>up to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (Cmax, AUC, CL/f, CLR, t1/2) before and after the first dose</measure>
    <time_frame>Day 1</time_frame>
    <description>Various pharmacokinetic parameters (Cmax, AUC, CL/f, CLR, t1/2) will be assessed before the first treatment and during the course of 12 hours after the first treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (Cmax, AUC, CL/f, CLR, t1/2) at steady state</measure>
    <time_frame>Week 4</time_frame>
    <description>Various pharmacokinetic parameters (Cmax, AUC, CL/f, CLR, t1/2) will be assessed during the course of 12 hours after 4 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of clinical events stage 3 or 4 of WHO HIV classification</measure>
    <time_frame>up to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events as Measure of safety and tolerability</measure>
    <time_frame>up to week 24</time_frame>
    <description>The number of Adverse Events and also the quality, severity and relatedness to study drug are documented and analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of resistance mutations after confirmed treatment failure (confirmed HIV RNA &gt; 1000 copies/ml</measure>
    <time_frame>at week 12 and week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>FZD 600mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FZD 3 tablets (600mg) twice daily / 3TC 1 tablet (150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FZD 800mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FZD 4 tablets (800mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FZD 1200mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FZD 6 tablets (1200mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZT twice daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet Combivir(AZT 300mg/3TC 150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FZD</intervention_name>
    <arm_group_label>FZD 1200mg once daily</arm_group_label>
    <arm_group_label>FZD 600mg twice daily</arm_group_label>
    <arm_group_label>FZD 800mg once daily</arm_group_label>
    <other_name>Fozivudine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3TC</intervention_name>
    <arm_group_label>AZT twice daily</arm_group_label>
    <arm_group_label>FZD 1200mg once daily</arm_group_label>
    <arm_group_label>FZD 600mg twice daily</arm_group_label>
    <arm_group_label>FZD 800mg once daily</arm_group_label>
    <other_name>Lamivudine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFV</intervention_name>
    <arm_group_label>AZT twice daily</arm_group_label>
    <arm_group_label>FZD 1200mg once daily</arm_group_label>
    <arm_group_label>FZD 600mg twice daily</arm_group_label>
    <arm_group_label>FZD 800mg once daily</arm_group_label>
    <other_name>Efavirenz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZT</intervention_name>
    <arm_group_label>AZT twice daily</arm_group_label>
    <other_name>Zidovudine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥ 18 years of age.&#xD;
&#xD;
          2. Provide written or thump printed informed consent prior to all trial-related&#xD;
             procedures&#xD;
&#xD;
          3. HIV-1 positive with an indication to start antiretroviral therapy (ART) according to&#xD;
             WHO and/or country guidelines&#xD;
&#xD;
          4. ART naïve, including no history of antiretroviral medication during PMTCT or PEP&#xD;
&#xD;
          5. Patient agrees not to take any concomitant medication during the trial without&#xD;
             informing the investigator. Traditional medicines should be specified with concomitant&#xD;
             medications.&#xD;
&#xD;
          6. Availability throughout the study&#xD;
&#xD;
          7. Female patients of childbearing potential must have a negative pregnancy test and&#xD;
             agree to use a highly effective method of birth control throughout participation in&#xD;
             the trial and for 10 weeks after last dose (to cover duration of ovulation).&#xD;
&#xD;
          8. Agree to have home visits or active tracing if lost to follow up or any other event&#xD;
             justifying a rapid visit of the patient at the clinical trial centre.&#xD;
&#xD;
          9. CD4 count ≥100 cells/μl&#xD;
&#xD;
         10. Hb ≥9.5 g/dl&#xD;
&#xD;
         11. Platelets ≥50,000 cells/mm3&#xD;
&#xD;
         12. Neutrophils ≥500 cells/ mm3&#xD;
&#xD;
         13. Bilirubin &lt;2.5 x uln&#xD;
&#xD;
         14. ALT &lt;2.5 x uln&#xD;
&#xD;
         15. Exclusion of Severe hepatic insufficiency (PT&lt;50%)&#xD;
&#xD;
         16. Creatinine clearance calculated by Cockroft's formula ≥50 ml/min&#xD;
&#xD;
         17. Urine dipstick for protein and blood: negative or trace&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Deficiency in the patient, rendering it difficult, if not impossible, for him/her to&#xD;
             take part in the trial or understand the information provided to him/her&#xD;
&#xD;
          2. Presence of an uncontrolled, ongoing, opportunistic infection or of any severe or&#xD;
             progressive disease including active TB or any other justified reason which in the&#xD;
             opinion of the investigator could significantly inhibit study procedures. This&#xD;
             includes any clinical signs possibly associated with any WHO stage 3 or 4, with still&#xD;
             unconfirmed diagnosis such as fever, weight loss, diarrhoea or unexplained cough.&#xD;
&#xD;
          3. HIV-2 infection&#xD;
&#xD;
          4. Pregnancy or lactating mother&#xD;
&#xD;
          5. Unlikely to comply with protocol as judged by the principal investigator or his&#xD;
             designate&#xD;
&#xD;
          6. Use of experimental therapeutic agents within 30 days of study entry.&#xD;
&#xD;
          7. Hepatitis B with positive HBsAg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hoelscher, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Department for Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Leopoldstrasse 5, 80802, Munich, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales, CHU de Treichville,</name>
      <address>
        <city>Abidjan</city>
        <zip>BPV3</zip>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIMR - Mbeya Medical Research Programme,</name>
      <address>
        <city>Mbeya</city>
        <zip>PO Box 2410</zip>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>October 25, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2012</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Michael Hoelscher</investigator_full_name>
    <investigator_title>Chief Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Fozivudine</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>FATI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

